Blood Cancer United's new research funding supports foundational science, AI, big data and global collaborations to improve patient outcomes WASHINGTON, Dec. 2, 2025 /PRNewswire/ ...
Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...
VigenCell, a company specializing in immune cell therapy, is moving toward early commercialization after presenting significant results in Phase 2 ...
Temferon shows consistent survival metrics in glioblastoma patients with unmethylated MGMT, with 44% reaching 18-month ...
Researchers sought to determine whether adding mogamulizumab to CHOP would improve outcomes in older patients with adult T-cell leukemia/lymphoma.
(hereinafter referred to as “Juventas”) announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) (tradename: YORWIDATM), has received new drug ...
Progress in the treatment of T-cell blood cancers – which are rare – has also been modest. So, much remains to be done to ...
Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...
The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback